Anatomy hub
Shoulder: Options and What the Evidence Actually Shows
Rotator cuff disease and glenohumeral osteoarthritis are the two highest-intent shoulder paths. Both have established surgical and non-surgical ladders.
Anatomy and clinical context
The shoulder trades stability for range of motion. The rotator cuff and labrum are common failure points; glenohumeral cartilage wear produces a different clinical picture.
Physical therapy and activity modification remain first-line for many cuff and OA presentations. Injections and surgery follow based on tear morphology, age, and function goals.
Illustration of the shoulder and rotator cuff
The standard-of-care ladder
Conservative care first, then injections, then surgery when indicated. Cell therapy belongs in that conversation — not above it.
- Step 1
Conservative care
Physical therapy, activity modification, and oral analgesics for many cuff and OA presentations.
- Step 2
Injections
Corticosteroid, PRP, and orthobiologic injectates in selected partial tears or early arthritis when a physician recommends them.
- Step 3
Surgery
Rotator cuff repair, reverse or anatomic arthroplasty, and other procedures for full-thickness tears or advanced arthritis.
Where cell therapy fits
Shoulder orthobiologic studies vary widely in product, dosing, and outcomes. Treat marketing claims skeptically; treat your physician's exam and imaging as the primary decision frame.
- Partial cuff tears and early OA are the scenarios most often discussed for regenerative injectates — not every tear or every arthritis stage.
- Same-day products remain limited by cell yield and donor age — the same dose story as knee OA.
- Banking preserves younger cells if a future course of care needs expansion beyond a single aspiration.
Selected citations
MILES
Mautner et al. · Nature Medicine (2023)
n=440 knee OA trial: BMAC, umbilical tissue, and SVF vs corticosteroid — none beat steroid at one year; none moved MRI scores.
Shapiro 2017
Shapiro et al. · AJSM (2017)
BMAC vs saline in the same patient's other knee — no difference on primary outcomes.
Cartistem
Approved product (Korea) · Regulatory approval (2012)
Culture-expanded allogeneic MSC product approved in Korea with structural signal in cartilage repair settings.
Why dose and donor age change the picture
The trials that disappoint used unexpanded cells from older donors.
The ones that work used expanded cells at therapeutic dose. Dose is the variable — and dose is what expansion buys you. Potency is what your age buys you.
- 1
Cells work at dose.
A same-day draw yields a small, uncounted, unexpanded fraction. Expansion turns one draw into many doses.
- 2
Potency is age-dependent, and it is a one-way door.
Your MSCs at 35 are not your MSCs at 55. Banking is the only mechanism that makes 35-year-old cells available to a 55-year-old.
- 3
Expansion is what makes the bank a supply, not a souvenir.
Bank once, expand repeatedly, across a treatment course rather than a single shot. Culture expansion for Forever Labs members is rolling out — starting with selected states as our Florida cGMP lab comes online.
- 4
The provider decides what happens next.
We supply cells; they practice medicine. Forever Labs does not treat conditions — your physician owns the clinical relationship.
Two next steps — equal weight
Forever Labs does not treat conditions. Your physician owns the clinical relationship. We bank cells and, as expansion rolls out, help make dose possible.